Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Significance of measured intraoperative portal vein flows after thrombendvenectomy in deceased donor liver transplantations with portal vein thrombosis.

Draoua M, Titze N, Gupta A, Fernandez HT, Ramsay M, Saracino G, McKenna G, Testa G, Klintmalm GB, Kim PTW.

Liver Transpl. 2017 Aug;23(8):1032-1039. doi: 10.1002/lt.24779.

2.

Inferior vena cava reconstruction for leiomyosarcoma of Zone I-III requiring complete hepatectomy and bilateral nephrectomy with autotransplantation.

Fernandez HT, Kim PT, Anthony TL, Hamman BL, Goldstein RM, Testa G.

J Surg Oncol. 2015 Oct;112(5):481-5. doi: 10.1002/jso.24041. Epub 2015 Sep 10.

PMID:
26356493
3.

Renal Autotransplantation in Lynch Syndrome: A Viable Option in a Patient With Contralateral Metachronous Ureteral Cancer.

Woods T, Jennings NB, Fernandez HT, Onaca N, Carlile BK, Levy MF, Gould DL, Ruiz R.

Am J Transplant. 2015 Sep;15(9):2507-10. doi: 10.1111/ajt.13279. Epub 2015 Apr 6.

4.

In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.

Goldstein EJ, Citron DM, Merriam CV, Warren YA, Tyrrell KL, Fernandez HT.

Antimicrob Agents Chemother. 2008 Feb;52(2):761-6. Epub 2007 Dec 10.

5.

In vitro activity of ceftobiprole against aerobic and anaerobic strains isolated from diabetic foot infections.

Goldstein EJ, Citron DM, Merriam CV, Warren YA, Tyrrell KL, Fernandez HT.

Antimicrob Agents Chemother. 2006 Nov;50(11):3959-62. Epub 2006 Sep 18.

6.

Comparative in vitro susceptibilities of 396 unusual anaerobic strains to tigecycline and eight other antimicrobial agents.

Goldstein EJ, Citron DM, Merriam CV, Warren YA, Tyrrell KL, Fernandez HT.

Antimicrob Agents Chemother. 2006 Oct;50(10):3507-13. Epub 2006 Aug 28.

7.

Bacteriology of human bite wound infections.

Merriam CV, Fernandez HT, Citron DM, Tyrrell KL, Warren YA, Goldstein EJ.

Anaerobe. 2003 Apr;9(2):83-6.

PMID:
16887692
8.

In vitro activities of dalbavancin and 12 other agents against 329 aerobic and anaerobic gram-positive isolates recovered from diabetic foot infections.

Goldstein EJ, Citron DM, Warren YA, Tyrrell KL, Merriam CV, Fernandez HT.

Antimicrob Agents Chemother. 2006 Aug;50(8):2875-9.

9.

In vitro activities of daptomycin, vancomycin, and penicillin against Clostridium difficile, C. perfringens, Finegoldia magna, and Propionibacterium acnes.

Tyrrell KL, Citron DM, Warren YA, Fernandez HT, Merriam CV, Goldstein EJ.

Antimicrob Agents Chemother. 2006 Aug;50(8):2728-31.

10.

Comparative in vitro activities of retapamulin (SB-275833) against 141 clinical isolates of Propionibacterium spp., including 117 P. acnes isolates.

Goldstein EJ, Citron DM, Merriam CV, Warren YA, Tyrrell KL, Fernandez HT.

Antimicrob Agents Chemother. 2006 Jan;50(1):379-81.

11.

Broth microdilution and disk diffusion tests for susceptibility testing of Pasteurella species isolated from human clinical specimens.

Citron DM, Warren YA, Fernandez HT, Goldstein MA, Tyrrell KL, Goldstein EJ.

J Clin Microbiol. 2005 May;43(5):2485-8.

13.
14.

In vitro activities of ABT-492, a new fluoroquinolone, against 155 aerobic and 171 anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitis.

Goldstein EJ, Citron DM, Merriam CV, Warren YA, Tyrrell KL, Fernandez HT.

Antimicrob Agents Chemother. 2003 Sep;47(9):3008-11.

15.

In vitro activities of dalbavancin and nine comparator agents against anaerobic gram-positive species and corynebacteria.

Goldstein EJ, Citron DM, Merriam CV, Warren Y, Tyrrell K, Fernandez HT.

Antimicrob Agents Chemother. 2003 Jun;47(6):1968-71.

16.

In vitro activities of daptomycin, vancomycin, quinupristin- dalfopristin, linezolid, and five other antimicrobials against 307 gram-positive anaerobic and 31 Corynebacterium clinical isolates.

Goldstein EJ, Citron DM, Merriam CV, Warren YA, Tyrrell KL, Fernandez HT.

Antimicrob Agents Chemother. 2003 Jan;47(1):337-41. Erratum in: Antimicrob Agents Chemother. 2003 Apr;47(4):1486.

17.

In vitro activities of Garenoxacin (BMS 284756) against 108 clinical isolates of Gardnerella vaginalis.

Goldstein EJ, Citron DM, Merriam CV, Warren YA, Tyrrell KL, Fernandez HT.

Antimicrob Agents Chemother. 2002 Dec;46(12):3995-6.

18.
19.

In vitro activities of garenoxacin (BMS-284756) against 170 clinical isolates of nine Pasteurella species.

Goldstein EJ, Citron DM, Merriam CV, Warren YA, Tyrrell KL, Fernandez HT.

Antimicrob Agents Chemother. 2002 Sep;46(9):3068-70.

20.

Pasteurella multocida subsp. multocida and P. multocida subsp. septica differentiation by PCR fingerprinting and alpha-glucosidase activity.

Hunt Gerardo S, Citron DM, Claros MC, Fernandez HT, Goldstein EJ.

J Clin Microbiol. 2001 Jul;39(7):2558-64.

Supplemental Content

Loading ...
Support Center